Next-Generation RNA Therapeutics and Vaccines Surge: Promising Modalities and Clinical Trials Fueling Growth in the RNA Market
October 12, 2023 05:43 ET
|
Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapeutics Market and RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical...
Global Influenza Vaccine Market Research Report 2023: A $12.32 Billion Market by 2028 Driven by Increased Vaccine Awareness, Post COVID-19
October 05, 2023 09:43 ET
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: Analysis by Valency, By Vaccine Type, By Technology, By Age Group, By Route Of Administration, By Distribution...
High Prevalence of RSV in Infants and Elderly Pushes RSV Vaccine and Antibody Market Growth - Forecast to 2030
September 28, 2023 04:58 ET
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Forecast up to 2030" report has been added to ResearchAndMarkets.com's...
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 26, 2023 16:01 ET
|
HilleVax, Inc.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Global COVID-19 Vaccines Strategic Business Analysis Report 2023-2025: With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking
September 25, 2023 08:58 ET
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global COVID-19 Vaccines Market to...
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Pricing of Public Offering of Common Stock
September 19, 2023 20:05 ET
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax Announces Proposed Public Offering of Common Stock
September 19, 2023 16:09 ET
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Global Influenza Vaccines Research Analysis Report 2023-2030: Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Vaccines in Clinical Development, Major Deals and Recent Developments
August 31, 2023 10:36 ET
|
Research and Markets
Dublin, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in Clinical...
Global Influenza Vaccines Research Analysis Report 2023-2030: Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Vaccines in Clinical Development, Major Deals and Recent Developments
August 31, 2023 10:34 ET
|
Research and Markets
Dublin, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in Clinical...